Synaffix, a company of Swiss drugmaker Lonza, has entered into a licensing agreement with South Korean biopharmaceutical firm Qurient to develop a dual-payload antibody-drug conjugate (ADC). Synaffix ...

Lonza is responsible for manufacturing proprietary tech components and Sidewinder for ADC, R&D, manufacturing, and commercialization.

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platformSidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 ...

AMSTERDAM, Jan. 9, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug ...

License from Synaffix focuses on bispecific ADCs This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation ...

PRAGUE & AMSTERDAM--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option ...

Presentations to highlight preclinical data supporting the clear differentiation of Adcentrx's clinical-stage ADRX-0405 STEAP1 ADC and preclinical ADRX-0134 NaPi2b ADC Adcentrx to present new ...

Antibody–drug conjugates (ADCs) in oncology have been some of the most sought-after assets in the biopharma dealmaking landscape in the past two years. For example, in 2023, Pfizer purchased Seagen, ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the ...